HOME >> BIOLOGY >> NEWS
Dartmouth professor makes case for ethically universal stem cell lines

HANOVER, NH -- Human embryonic stem cells (hESC), those very young cells that are a biological blank slate, have the potential to become more specialized, contributing to the workings of a wide variety of organs and tissues. Their potential to treat diseases such as Parkinsons is slow to be realized because of the ongoing ethical debate over harvesting hESCs, a process called deriving hESC lines. Additionally, its a politically charged issue in the U.S. because it involves federal funding for research.

A recently published paper by Dartmouth Professor Ronald M. Green examines the moral questions and the scientific feasibility of deriving hESC lines in ways that avoid destroying living human embryos. The paper, published in the June 2007 issue of Nature Reviews Genetics, considers six current approaches: altered nuclear transfer, parthenogenesis, single-blastomere biopsy, somatic-cell dedifferentiation, the use of dead embryos, and the use of abnormal embryos. Greens goal, as stated in the paper, is to greatly accelerate hESC research that is closer to being universally acceptable.

I think we can pursue hESC research and also respect the sensitivities of our fellow citizens. Its not impossible to do both, says Green, the Eunice and Julian Cohen Professor for the Study of Ethics and Human Values, and the faculty director of the Dartmouth Ethics Institute. In addition to resolving current debates, he argues, these alternatives can make possible hESC lines that are ethically universal. These would be analogous to the universal O-type blood group: lines that could be used by anyone regardless of their ethical views on the moral status of the embryo.

Green, who is also an adjunct professor of community and family medicine at the Dartmouth Medical School, says, The six approaches differ in technique, most directly in how the blastocyst is created. The blastocyst, where hESCs are found, is the three- to five-day-old embryo that has not yet
'"/>

Contact: Sue Knapp
sue.knapp@dartmouth.edu
603-646-3661
Dartmouth College
7-Jun-2007


Page: 1 2

Related biology news :

1. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
2. Vitamin extends life in yeast, Dartmouth Medical School researchers find
3. Dartmouth researchers find that arsenic triggers unique mechanism in rare leukemia
4. Dartmouth researchers find that low doses of arsenic have broad impact on hormone activity
5. Dartmouth researchers identify a gene that enhances muscle performance
6. Dartmouth study contributes to research addressing malnutrition and iron deficiency
7. Genetic variation impacts aspirins effectiveness in preventing colon cancer, Dartmouth study finds
8. Dartmouth researchers find a neural signature of bilingualism
9. Dartmouth and GlycoFi report full humanization of therapeutic proteins from yeast
10. GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science
11. Dartmouth researchers find key player in immune system regulation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
Cached News: